Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose versus full-dose alteplase for high-risk pulmonary embolism
2024-515904-37-00Phase 4Authorised
- Sponsor
- Region Västra Götaland
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial of tissue-plasminogen activator in pulmonary embolism (PE) (2 arms), sponsored by Region Västra Götaland. Primary endpoint: Primary efficacy endpoint. Planned start Sep 2026; status: authorised.
02
Drugs
tissue-plasminogen activator
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on 2024-515904-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515904-37-00.